Crinetics Pharmaceuticals (CRNX) Gains from Investment Securities (2017 - 2026)

Crinetics Pharmaceuticals' Gains from Investment Securities history runs 10 years deep, the most recent figure standing at -$20000.0 for Q1 2026.

• In Q1 2026, Gains from Investment Securities fell 100.13% year-over-year to -$20000.0; the TTM figure through Mar 2026 stood at $73000.0 (down 99.52% YoY), while the FY2024 annual figure was $13.7 million, up 8.23% from the prior year.
• Gains from Investment Securities was -$20000.0 for Q1 2026 at Crinetics Pharmaceuticals, down from $42000.0 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $46.3 million in Q4 2023 to a low of -$5.6 million in Q4 2022.
• Historically, Gains from Investment Securities has averaged $7.6 million across 5 years, with a median of $2.9 million in 2022.
• Biggest YoY gain for Gains from Investment Securities was 343359.55% in 2022; the steepest drop was 70100.0% in 2022.
• A 5-year view of Gains from Investment Securities shows it stood at -$5.6 million in 2022, then jumped by 926.41% to $46.3 million in 2023, then slumped by 99.89% to $51000.0 in 2024, then decreased by 17.65% to $42000.0 in 2025, then tumbled by 147.62% to -$20000.0 in 2026.
• The last three Gains from Investment Securities figures came in at -$20000.0 (Q1 2026), $42000.0 (Q4 2025), and $15.0 million (Q2 2025), per Business Quant data.